Dr Mike Trower

Dr Mike Trower is a Co-Founder and Chief Scientific Officer of NeRRe Therapeutics

Mike is a Co-Founder and Chief Scientific Officer (CSO) of NeRRe Therapeutics, who championed the potential that next generation neurokinin-1 receptor antagonists, such as the company’s lead clinical asset orvepitant, could present an exciting new approach to effectively treat neuronal hypersensitivity disorders with significant unmet need including chronic refractory cough.  Orvepitant is currently in a multi-national Phase 2 trial for cough associated with idiopathic pulmonary fibrosis. 

Mike was also Co-founder and CSO of KaNDy Therapeutics a Women’s Health company focussed on developing elinzanetant, a dual mechanism neurokinin-1,3 receptor antagonist, as a novel and truly transformational non-hormonal therapy for treatment of symptoms of the menopause and related Women’s Health conditions.  KaNDy was acquired by Bayer Pharmaceuticals in September 2020.

Prior to founding NeRRe, Mike worked in pharmaceutical industry R&D at GSK for nearly 20 years, where latterly he was VP & Head of the External Drug Discovery in the Neurosciences Division.

Mike has BSc (Hons) and PhD degrees in biological sciences and has held post-doctoral positions at DuPont Inc in Delaware, US, and at the Medical Research Council in Cambridge, UK, under the Nobel laureate Professor Sydney Brenner.